REFOCUS GROUP RECEIVES FDA APPROVAL TO INITIATE FINAL PHASE OF SSP CLINICAL TRIAL FOR PRESBYOPIA

Refocus Group, Inc. (OTC: RFCG.OB - News; www.refocus-group.com), a medical device company engaged in the research and development of treatments for eye disorders, today announced it has received approval from the U.S. Food and Drug Administration to begin enrollment for the final round of clinical trial surgeries for the company's Scleral Spacing Procedure (SSP) for the surgical treatment of presbyopia.

Yahoo News (http://biz.yahoo.com/prnews/050824/clw044.html?.v=20)